Amanda Scherer

Amanda Scherer

Auto-generated profile, based on publicly available information

Amanda Scherer

Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA 52240, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
JKJordan Kohlmeyer
Jordan Kohlmeyer
JLJoshua James Lingo
Joshua James Lingo
CKCourtney A. Kaemmer
Courtney A. Kaemmer
ASAmanda Scherer
Amanda Scherer
AWAkshaya Warrier
Akshaya Warrier
DQDawn Quelle
Dawn Quelle
Purpose: Malignant peripheral nerve sheath tumors (MPNST) are lethal, Ras-driven sarcomas that lack effective therapies. We investigated effects of targeting cyclin-dependent kinases 4 and 6 (CDK4/6), MEK, and/or programmed death-ligand 1 (PD-L1) in preclinical MPNST models. Experimental Design: Patient-matched MPNSTs and precursor lesions were examined by FISH, RNA sequencing, IHC, and Connectivity-Map analyses. Antitumor activity of CDK4/6 and MEK inhibitors was measured in MPNST cell lines, patient-derived xenografts (PDX), and de novo mouse MPNSTs, with the latter used to determine anti–PD-L1 response. Results: Patient tumor analyses identified CDK4/6 and MEK as actionable targets for MPNST therapy. Low-dose combinations of CDK4/6 and MEK inhibitors synergistically reactivated the retinoblastoma (RB1) tumor suppressor, induced cell death, and decreased clonogenic survival of MPNST cells. In immune-deficient mice, dual CDK4/6-MEK inhibition slowed tumor growth in 4 of 5 MPNST PDXs. In immunocompetent mice, combination therapy of de novo MPNSTs caused tumor regression, delayed resistant tumor outgrowth, and improved survival relative to monotherapies. Drug-sensitive tumors that regressed contained plasma cells and increased cytotoxic T cells, whereas drug-resistant tumors adopted an immunosuppressive microenvironment with elevated MHC II-low macrophages and increased tumor cell PD-L1 expression. Excitingly, CDK4/6-MEK inhibition sensitized MPNSTs to anti–PD-L1 immune checkpoint blockade (ICB) with some mice showing complete tumor regression. Conclusions: CDK4/6-MEK inhibition induces a novel plasma cell-associated immune response and extended antitumor activity in MPNSTs, which dramatically enhances anti–PD-L1 therapy. These preclinical findings provide strong rationale for clinical translation of CDK4/6-MEK-ICB targeted therapies in MPNST as they may yield sustained antitumor responses and improved patient outcomes.

15 August 2025 in Science Advances
Verified
Journal Article
Open access
GMGavin R. McGivney
Gavin R. McGivney
QBQierra R. Brockman
Qierra R. Brockman
NBNicholas C. Borcherding
Nicholas C. Borcherding
ASAmanda Scherer
Amanda Scherer
ARAdam Rauckhorst
Adam Rauckhorst
RDRebecca Dodd
Rebecca Dodd
Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive and chemo-resistant sarcomas with poor survival rates. Loss of CDKN2A or P53 following NF1 disruption is a key event in MPNST development. Here, we used CRISPR-Cas9 somatic tumorigenesis in mice to identify transcriptomic and metabolomic features distinguishing CDKN2A - versus P53 -deleted MPNSTs. Convergent, multiomic analyses revealed that CDKN2A -deleted MPNSTs are especially dependent on the pentose phosphate pathway (PPP) and NADPH metabolism for growth and viability. Disruption of glucose-6-phosphate dehydrogenase (G6PD), the PPP rate-limiting enzyme, slowed CDKN2A -deleted MPNST growth and sensitized MPNSTs to standard-of-care chemotherapy. Knockdown of the redox-regulated transcription factor NRF2 slowed MPNST growth and decreased G6PD transcription. Analysis of patient MPNSTs identified a NRF2 gene signature correlating with tumor transformation. Furthermore, G6PD and NRF2 expression in PanCancer TCGA samples correlates with patient survival. This work identifies NRF2-PPP dependency as a targetable vulnerability in these difficult-to-treat MPNSTs, particularly in the NF1/CDKN2A -deleted majority.

25 November 2025
Verified
Other
Open access
JKJordan Kohlmeyer
Jordan Kohlmeyer
JLJoshua James Lingo
Joshua James Lingo
CKCourtney A. Kaemmer
Courtney A. Kaemmer
ASAmanda Scherer
Amanda Scherer
AWAkshaya Warrier
Akshaya Warrier
DQDawn Quelle
Dawn Quelle
Supplementary Figure S2. Dual CDK4/6-MEK inhibition synergistically suppresses the growth of some, but not all, MPNST PDXs in immune deficient mice

25 July 2023
Verified
Other
Open access
PDF file
JKJordan Kohlmeyer
Jordan Kohlmeyer
JLJoshua James Lingo
Joshua James Lingo
CKCourtney A. Kaemmer
Courtney A. Kaemmer
ASAmanda Scherer
Amanda Scherer
AWAkshaya Warrier
Akshaya Warrier
DQDawn Quelle
Dawn Quelle
Supplementary Figure S3. Tumor growth kinetics of individual de novo MPNSTs during therapy

25 July 2023
Verified
Other
Open access
PDF file
JKJordan Kohlmeyer
Jordan Kohlmeyer
JLJoshua James Lingo
Joshua James Lingo
CKCourtney A. Kaemmer
Courtney A. Kaemmer
ASAmanda Scherer
Amanda Scherer
AWAkshaya Warrier
Akshaya Warrier
DQDawn Quelle
Dawn Quelle
Supplementary Table S4. Primers for qRT-PCR analyses

25 July 2023
Verified
Other
Open access
PDF file
JKJordan Kohlmeyer
Jordan Kohlmeyer
JLJoshua James Lingo
Joshua James Lingo
CKCourtney A. Kaemmer
Courtney A. Kaemmer
ASAmanda Scherer
Amanda Scherer
AWAkshaya Warrier
Akshaya Warrier
DQDawn Quelle
Dawn Quelle
Supplementary Figure S5. Evaluation of differentially expressed genes (DEGs) and tumor infiltrating immune cells (plasma cells and B cells) in drug-treated de novo MPNSTs.